share_log

Canaccord Genuity Group Begins Coverage on GreenLight Biosciences (NASDAQ:GRNA)

Canaccord Genuity Group Begins Coverage on GreenLight Biosciences (NASDAQ:GRNA)

卡雅克誠集團開始覆蓋綠光生物科學 (NASDAQ: GRNA)
kopsource ·  2022/12/11 04:42

Canaccord Genuity Group began coverage on shares of GreenLight Biosciences (NASDAQ:GRNA – Get Rating) in a research report sent to investors on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $4.00 target price on the stock.

康合誠集團開始覆蓋股份 綠光生物科學 (納斯達克:GRNA — 獲得評分) 在星期四發送給投資者的研究報告中，MarketBeat 評級報告。該經紀公司發布了買入評級和 4.00 美元的股票目標價。

Separately, Credit Suisse Group began coverage on GreenLight Biosciences in a research report on Friday, October 14th. They set an outperform rating and a $5.50 price target on the stock.

另外，瑞士信貸集團於 10 月 14 日（星期五）在一份研究報告中開始對綠光生物科學進行報導。他們在股票上設定了「跑贏大市」評級和 5.50 美元的目標價格。

Get
取得
GreenLight Biosciences
綠光生物科學
alerts:
警報：

GreenLight Biosciences Trading Up 3.6 %

綠光生物科學交易上升 3.6%

Shares of GreenLight Biosciences stock opened at $1.14 on Thursday. The business's fifty day moving average price is $1.76 and its two-hundred day moving average price is $2.75. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.20. GreenLight Biosciences has a 1-year low of $1.05 and a 1-year high of $15.80.

綠光生物科學股票在周四開盤 1.14 美元。該企業的五十天移動平均價格為 1.76 美元，其 200 天移動平均價格為 2.75 美元。該公司的快速比率為 3.37，流動比率為 3.37，債務與權益比率為 0.20。綠光生物科學的 1 年低點為 1.05 美元，1 年新高為 15.80 美元。

Hedge Funds Weigh In On GreenLight Biosciences

對沖基金權衡綠光生物科學

A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in shares of GreenLight Biosciences by 340.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 213,329 shares of the company's stock worth $495,000 after acquiring an additional 164,893 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of GreenLight Biosciences by 47.2% in the 3rd quarter. California State Teachers Retirement System now owns 71,001 shares of the company's stock worth $165,000 after acquiring an additional 22,773 shares during the last quarter. Baird Financial Group Inc. acquired a new position in shares of GreenLight Biosciences in the 3rd quarter worth $6,628,000. State Street Corp grew its holdings in shares of GreenLight Biosciences by 108.2% in the 3rd quarter. State Street Corp now owns 811,721 shares of the company's stock worth $1,883,000 after acquiring an additional 421,797 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of GreenLight Biosciences by 29.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,205,436 shares of the company's stock worth $2,797,000 after acquiring an additional 274,020 shares during the last quarter. 23.94% of the stock is currently owned by institutional investors and hedge funds.
一些對沖基金最近修改了他們對該股票的持有量。紐約梅隆銀行在第三季度增加了其在 GreenLight 生物科學股份的持有量達 340.4%。紐約梅隆銀行在上一季度額外購入 164,893 股股份後，現在擁有該公司股票的 213,329 股價值 495,000 美元。加利福尼亞州教師退休制度在第三季度增長了 47.2％ 的綠光生物科學股份的持有量。加利福尼亞州教師退休制度現在擁有該公司股票的 71,001 股價值 165,000 美元，在上個季度額外購買了 22,773 股。貝爾德金融集團股份有限公司在第三季度收購了綠光生物科學股份的新職位，價值 6,628,000 美元。州街公司在第三季度增長了其在綠光生物科學股份的持有量 108.2％。州街公司現在擁有該公司股票的 811,721 股，價值 1,883,000 美元，在上個季度額外收購了 421,797 股股票。最後，先鋒集團股份有限公司在第三季度增長了 29.4％ 的綠光生物科學股份。領航集團在上一季度額外收購 274,020 股股份後，現在擁有該公司股票的 1,205,436 股價值 2,797,000 美元。23.94％ 的股票目前由機構投資者和對沖基金擁有。

GreenLight Biosciences Company Profile

綠光生物科學公司簡介

(Get Rating)

(取得評分)

GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

綠光生物科學控股是一家生物技術公司，生產和銷售核糖核酸（RNA）產品，用於人類健康和農業應用。其對人體健康的產品包括 mRNA 疫苗和治療藥物；以及用於保護蜜蜂和農作物的農業 RNA 產品。該公司成立於 2008 年，總部位於馬薩諸塞州梅德福。

Featured Stories

特色故事

  • Get a free copy of the StockNews.com research report on GreenLight Biosciences (GRNA)
  • MarketBeat: Week in Review 12/05 – 12/09
  • There Is Fundamental Value In Broadcom, And It Yields 3.35%
  • Costco vs Amazon: an end of the year showdown
  • Discount Retailers Could Make Good Bargain Stocks
  • Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
  • 免費獲取綠光生物科學研究報告
  • 市場節拍：評論中的一周
  • 有博通的基本價值, 它產生 3.35%
  • 好市多 vs 亞馬遜：年底對決
  • 折扣零售商可以做好討價還價的股票
  • 輝瑞、強生能否繼續表現優於指數？

Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

接收綠光生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 GreenLight 生物科學及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論